Physician profile
Ronit Sharma
NPI 1780270538
$42,390.76
in general payments reported to CMS, 2019-2025
20 companies · $8,633 in 2025
The $8,633 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $537 · 2022: $4,113 · 2023: $17K · 2024: $12K · 2025: $8,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $7,917 · Travel and Lodging: $2,041 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,675.00 |
| Food and Beverage | $7,917.18 |
| Travel and Lodging | $2,040.64 |
| Education | $108.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35,494.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,589.93 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $916.45 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $864.35 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Alkermes, INC. | $810.40 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $712.05 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $504.08 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $473.91 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $259.69 | 2021-2025 | Trintellix |
| Lundbeck LLC | $212.44 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $108.99 | 2024-2025 | Cobenfy |
| Indivior INC. | $90.06 | 2022-2024 | Sublocade |
| Tempus Ai, INC | $79.74 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $76.26 | 2024-2025 | Uzedy, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $54.90 | 2022-2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $43.24 | 2024-2025 | Loreev Xr |
| Braeburn INC. | $38.98 | 2024-2025 | Brixadi |
| Bausch Health US, LLC | $28.98 | 2021-2022 | |
| Corium, LLC | $17.27 | 2024 | Azstarys |
| Hologic Sales and Service, LLC | $14.81 | 2024 | Myosure Tissue Removal Device, Novasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronit Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.